Recbio And Rongsheng Biotech Signed a Strategic Cooperation Agreement On The New Adjuvant Vaccine Project
TAIZHOU, China, March 27, 2024 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (hereafter referred to as Recbio; stock code: 02179.HK) and?Shanghai Rongsheng Biotech Co.,Ltd.(hereafter referred to as "Rongsheng Biotech") successfully held a signing and project launch meeting for new adjuvant ...
Jiangsu Recbio Technology Co., Ltd. announced 2023 annual results report and latest progress
TAIZHOU, China, March 21, 2024 /PRNewswire/ -- Innovative vaccine company Recbio (02179.HK) announced its latest progress and annual results for 2023. The company always adhered to the mission of " Protect Human Health With Best-In-Class Vaccines", and achieved the following milestones and progre...
Positive Results In The Interim Analysis Of The Clinical Trial Of Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines
TAIZHOU, China, Dec. 29, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the novel adjuvanted recombinant shingles vaccine REC610 independently developed by the Company has recently achieved positive...
Recbio appeared at the 14th China (Taizhou) International Pharmaceutical Fair
TAIZHOU, China, Oct. 24, 2023 /PRNewswire/ -- From October 19 to 22, the 14th China (Taizhou) International Pharmaceutical Fair, sponsored by the China Chamber of International Commerce and hosted by the Taizhou Municipal People's Government andJiangsu Branch of the China Council for the Promotio...
Recbio signed a strategic cooperation agreement with Zimbabwe National Biotechnology Administration and ICGEB China Regional Research Centre
TAIZHOU, China, Oct. 10, 2023 /PRNewswire/ -- On October 8, 2023, Dr. Deckster Tonny SAVADYE, CEO of Zimbabwe NBA, and Dr.Yang Yili, International Centre for Genetic Engineering and Biotechnology China Regional Research Centre(ICGEB), visited Recbio. Dr. SAVADYE and his team conducted an on-the-s...
Jiangsu Recbio Technology Co., Ltd. announced 2023 interim results report and latest progress
TAIZHOU, China, Aug. 28, 2023 /PRNewswire/ -- Innovative vaccine company Recbio (02179.HK) announced its latest progress and interim results for 2023. During the reporting period, the company always adhered to the mission of " Protect Human Health With Best-In-Class Vaccines", rapidly promoted pr...
Acceptance Of Clinical Trial Application For The Recbio's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In China And Overseas Clinical Trial Progress
TAIZHOU, China, July 27, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the"Board") is pleased to announce that the Group has recently received the notice of acceptance (acceptance number: CXSL2300518) issued by National Medical Products Administration ("NMPA"), pursuant to which the c...
Inclusion of Recbio In the MSCI China Small Cap Index
TAIZHOU, China, May 17, 2023 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, MSCI announced the results of the semi-annual review of the MSCI Global Small Cap Indexes onMay 12, 2023, and the Company has ...
Two-Component Recombinant COVID-19 Vaccine ReCOV Granted With Emergency Use Authorization In Mongolia
TAIZHOU, China, March 21, 2023 /PRNewswire/ --?Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that in accordance with the Mongolian law on the prevention of novel coronavirus (SARS-CoV-2) outbreak, the Company was granted an...
Completion Of The First Batch Of Subject Enrollment For The Phase I Clinical Trial Of The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610
TAIZHOU, China, Feb. 13, 2023 /PRNewswire/ --?Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group has recently completed the first batch of subject enrollment for its novel adjuvanted recombinant shingles vaccine, ...
Superior Neutralizing Antibody Titer Levels Against Omicron BF.7 And BA.2.75 Of The Company's Two-Component Recombinant COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine
TAIZHOU, China, Dec. 26, 2022 /PRNewswire/ --?Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant two-component COVID-19...
Clinical Trial Approval For The Company's Novel Adjuvanted Recombinant Shingles Vaccine REC610 In The Philippines
TAIZHOU, China, Dec. 19, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, the Group has recently received the clinical trial approval for its novel adjuvanted recombinant shingles vaccine, REC610, fr...
Superior Results Of The Comparative Study Of The Company's Recombinant Two-Component COVID-19 Vaccine ReCOV As Compared To International Mainstream mRNA Vaccine
TAIZHOU, China, Dec. 14, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results were achieved for its sequential booster vaccination Phase II study of the recombinant twocomponent COVID-19 ...
Jiangsu Recbio Technology Co., Ltd. Increases Production For The First Phase Of Manufacturing Facility With A Maximum Annual Output Of 20 Million Doses Of Recombinant HPV 9-Valent Vaccine
TAIZHOU, China, Nov. 21, 2022 /PRNewswire/ -- ?(the "Company", together with its subsidiaries, the "Group") on voluntary basis. The board of directors of the Company (the "Board") is pleased to announce that in order to meet the rapidly growing market demand for HPV 9-valent vaccines inChina and ...
Update on overseas clinical trials progress of novel adjuvant COVID-19 vaccine ReCOV
TAIZHOU, China, Nov. 8, 2022 /PRNewswire/ --?Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that positive results were achieved for its primary vaccination Phase II study inthe Philippines and heterologous booster vaccinatio...
Acceptance Of The Application For Clinical Trial Of Recbio Novel Adjuvanted Recombinant Quadrivalent HPV Vaccine
TAIZHOU, China, Oct. 28, 2022 /PRNewswire/ --?Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group")? is pleased to announce that, the Group has recently received a notice of acceptance from the National Medical Products Administration to accept the appli...
Recbio Announces Interim results for the Fiscal Year 2022 and Company Progress
* The nine-valent HPV vaccine and other blockbuster varieties have been advanced efficiently. * Cash reserve was nearly RMB 1.5 billion, which provided support to sustainable innovation and commercialization. * The novel adjuvants vaccine will create a strong growth engine. TAIZHOU, China, ...
Completion Of Subject Enrollment And Vaccination For The Comparative Study Between ReCOV And mRNA Vaccines
TAIZHOU, China, Aug. 19, 2022 /PRNewswire/ --?Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, the Company has completed the subject enrollment and dosing for the comparative Phase II clinical trial between its recombina...
Recbio announces Phase III Clinical Trial Progress Of Recombinant HPV 9-Valent Vaccine
TAIZHOU, China, Aug. 10, 2022 /PRNewswire/ --?Jiangsu Recbio Technology Co., Ltd. (the"Company", together with its subsidiaries, the "Group", Stock code: 02179.HK) is pleased to announce that, the Company has recently completed the subject enrollment and first dose vaccination in respect of immun...
Approval Of The Comparative Study Between ReCOV And mRNA Vaccines By FDA In The Philippines
TAIZHOU, China, Aug. 3, 2022 /PRNewswire/ --?Jiangsu Recbio Technology Co., Ltd. (the"Company", together with its subsidiaries, the "Group",Stock code:02179.HK) is pleased to announce that, the Company has recently received the clinical trial approval for its recombinant protein COVID-19 vaccine,...
